Erschienen in:
01.08.2012 | Gastrointestinal Oncology
Nodal Counts on MDCT as a Surrogate Marker for Surgical Curability in Gastric Cancer
verfasst von:
Tsutomu Kawaguchi, MD, Shuhei Komatsu, MD, Daisuke Ichikawa, MD, Kazuma Okamoto, MD, Atsushi Shiozaki, MD, Hitoshi Fujiwara, MD, Yasutoshi Murayama, MD, Yoshiaki Kuriu, MD, Hisashi Ikoma, MD, Masayoshi Nakanishi, MD, Toshiya Ochiai, MD, Yukihito Kokuba, MD, Tsunehiko Nishimura, MD, Eigo Otsuji, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2012
Einloggen, um Zugang zu erhalten
Abstract
Background
Thin-slice multidetector row computed tomography (MDCT) has emerged as a promising diagnostic modality in various cancers. This study was designed to evaluate the utility of metastatic nodal counts on MDCT as a surrogate maker for surgical curability in gastric cancer.
Methods
Between 2005 and 2007, a total of 92 patients with gastric cancer underwent preoperative MDCT at a slice thickness of 1.0 mm at our hospital. All regional lymph nodes showing metastatic involvement were preoperatively counted.
Results
Although the total counts of metastatic lymph nodes on MDCT were significantly smaller than those found by histopathology (P = 0.00001), there was a significant correlation between nodal counts on MDCT and histopathology by Spearman’s analysis [P < 0.0001, pathologic counts = 1.63x (counts on MDCT) + 2.5]. Nodal counts on MDCT of ≥4 were analyzed as putative pathologic nodal counts of ≥8 by the equation, and pathologic metastatic nodal counts of ≥8 were most significantly correlated with noncurative resection (P < 0.0001). According to the logistic regression analysis, nodal counts on MDCT of ≥4 were a significant independent variable for noncurative resection (P = 0.0052, odds ratio 26.68). Nodal counts on MDCT of ≥4 could distinguish noncurative patients from curative patients with 94.4% sensitivity and 71.6% specificity.
Conclusions
Nodal counts on MDCT could be a reliable surrogate maker for surgical curability of gastric cancer. This marker might enable us to select prospective candidates for additional or alternative treatments in gastric cancer.